On April 14, 2023 Flamingo Therapeutics ("Flamingo") reported a presentation at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida (Press release, Flamingo Therapeutics, APR 14, 2023, View Source;utm_medium=rss&utm_campaign=flamingo-therapeutics-announces-poster-presentation-on-ftx-001-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting [SID1234630083]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Flamingo will present preclinical results highlighting the candidate selection and characterization of FTX-001, a novel antisense oligonucleotide targeting MALAT1 for the treatment of cancer. Flamingo is currently advancing FTX-001 through Phase 1 enabling preclinical activities and is planning for a First-in-Human trial in solid tumors.

Details of the poster presentation are below:

Title: "Preclinical development of FTX-001: First-in-class inhibitor of the long non-coding RNA MALAT1"

Session Category: Experimental and Molecular Therapeutics
Session Title: New Drug Targets
Session Date and Time: Sunday Apr 16, 2023, 1:30 PM – 5:00 PM
Location: Poster Section 16
Poster Board Number: 14
Published Abstract Number: 450

Abstracts and full session details are available through the AACR (Free AACR Whitepaper) Annual Meeting planner: AACR (Free AACR Whitepaper) Annual Meeting 2023 | Meetings | AACR (Free AACR Whitepaper)